Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.77 USD
Change Today -0.85 / -7.31%
Volume 4.2M
NVAX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 4:30 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Stanley C. Erck

Chief Executive Officer, President, Director and Member of Finance Committee,Novavax, Inc.
AgeTotal Calculated CompensationThis person is connected to 20 board members in 3 different organizations across 4 different industries.

See Board Relationships
67$3,081,024
As of Fiscal Year 2014

Background*

Mr. Stanley C. Erck, also known as Stan, has been the Chief Executive Officer and President at Novavax, Inc. since April 2011. Mr. Erck served as the Chief Executive Officer and President of Intercell USA Inc. from May 2000 to 2008 and served as its Treasurer since May 2000. Mr. Erck has over 25 years of management experience in the healthcare and biotechnology industry to shepherd the development and commercialization of Iomai technology. He managed the process of developing ...

Read Full Background

Corporate Headquarters*

20 Firstfield Road
Gaithersburg, Maryland 20878

United States

Phone: 240-268-2000
Fax: --

Board Members Memberships*

2005-Present
Director
2008-Present
Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Finance Committee
2009-Present
Chief Executive Officer, President, Director and Member of Finance Committee

Education*

MBA
The University of Chicago
BS
University of Illinois-Urbana-Champaign

Other Affiliations*

Annual Compensation*

Salary$487,750
Total Annual Compensation$487,750

Stock Options*

All Other Compensation$7,650
Exercisable Options1,482,500
Unexercisable Options2,237,500
Total Number of Options3,720,000

Total Compensation*

Total Annual Cash Compensation$800,244
Total Short Term Compensation$487,750
Other Long Term Compensation$7,650
Total Calculated Compensation$3,081,024
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $10.77 USD -0.85

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
J. Joseph Kim Ph.D.Chief Executive Officer, President, Director and Member of Finance Committee
Inovio Pharmaceuticals, Inc.
$964.7K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$555.7K
Eddie Gray Chief Executive Officer and Director
Dynavax Technologies Corporation
$515.0K
Stephen T. Isaacs Chairman, Chief Executive Officer and President
Aduro BioTech, Inc.
$886.6K
Laurence James Neil Cooper Ph.D., M.D.Chief Executive Officer
ZIOPHARM Oncology, Inc.
--
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.